TrialLancet (London, England)2025

Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China.

Anwen Xiong et al.PubMed ↗Publisher ↗

No numbers read from the abstract.